BioLife Solutions, the leading developer, manufacturer, and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies acquires SAVSU Technologies, the first commercial company to develop and market precision cold chain management tools specifically designed to overcome the challenges unique to commercializing cell and gene therapies. Financial terms were not disclosed. The acquisition of SAVSU is expected to further strengthen BioLife's position as a leading supplier of disruptive, enabling solutions used in the collection, manufacture, storage and distribution of cell and gene therapies. The transaction includes all SAVSU intellectual property comprised of 15 pending and issued U.S. patents related to cold chain technologies. Twenty-three SAVSU employees are joining the BioLife team and will remain in the design, engineering and fabrication facility in Albuquerque, New Mexico. SAVSU also has a contract sales organization covering Europe. "We see the integration into BioLife as a natural progression in the development and growth of SAVSU. We have worked closely with BioLife since 2014 and they have been a great supporter of our mission." Dana Barnard, SAVSU CEO.